TELA Bio (TELA) Competitors

$0.90 -0.09 (-8.59%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$0.90 -0.01 (-0.55%)

As of 05/15/2026 06:30 PM Eastern

TELA vs. PDEX, KRMD, INGN, INFU, and HYPR

Should you buy TELA Bio stock or one of its competitors? MarketBeat compares TELA Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TELA Bio include Pro-Dex (PDEX), KORU Medical Systems (KRMD), Inogen (INGN), InfuSystem (INFU), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry.

How does TELA Bio compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 45.9% of Pro-Dex shares are held by company insiders. Comparatively, 4.7% of TELA Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pro-Dex has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$74.64M	2.54	$8.98M	$3.62	16.37
TELA Bio	$80.28M	0.50	-$38.83M	-$0.79	N/A

Pro-Dex presently has a consensus price target of $70.00, suggesting a potential upside of 18.10%. TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 143.09%. Given TELA Bio's higher possible upside, analysts clearly believe TELA Bio is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pro-Dex has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

In the previous week, Pro-Dex and Pro-Dex both had 9 articles in the media. Pro-Dex's average media sentiment score of 1.37 beat TELA Bio's score of -0.02 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TELA Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 16.08% compared to TELA Bio's net margin of -49.30%. Pro-Dex's return on equity of 22.78% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
TELA Bio	-49.30%	-1,320.81%	-55.83%

Summary

Pro-Dex beats TELA Bio on 10 of the 15 factors compared between the two stocks.

How does TELA Bio compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

KORU Medical Systems currently has a consensus price target of $7.25, suggesting a potential upside of 85.90%. TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 143.09%. Given TELA Bio's higher possible upside, analysts clearly believe TELA Bio is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 4.7% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, TELA Bio had 8 more articles in the media than KORU Medical Systems. MarketBeat recorded 9 mentions for TELA Bio and 1 mentions for KORU Medical Systems. KORU Medical Systems' average media sentiment score of 1.89 beat TELA Bio's score of -0.02 indicating that KORU Medical Systems is being referred to more favorably in the media.

Company	Overall Sentiment
KORU Medical Systems	Very Positive
TELA Bio	Neutral

KORU Medical Systems has a net margin of -5.27% compared to TELA Bio's net margin of -49.30%. KORU Medical Systems' return on equity of -13.61% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
TELA Bio	-49.30%	-1,320.81%	-55.83%

KORU Medical Systems has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

KORU Medical Systems has higher earnings, but lower revenue than TELA Bio. KORU Medical Systems is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$43.26M	4.14	-$2.64M	-$0.05	N/A
TELA Bio	$80.28M	0.50	-$38.83M	-$0.79	N/A

Summary

KORU Medical Systems beats TELA Bio on 10 of the 16 factors compared between the two stocks.

How does TELA Bio compare to Inogen?

TELA Bio (NASDAQ:TELA) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Inogen has higher revenue and earnings than TELA Bio. Inogen is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.50	-$38.83M	-$0.79	N/A
Inogen	$348.67M	0.50	-$22.75M	-$0.91	N/A

TELA Bio has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Inogen has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

In the previous week, TELA Bio had 7 more articles in the media than Inogen. MarketBeat recorded 9 mentions for TELA Bio and 2 mentions for Inogen. Inogen's average media sentiment score of 0.93 beat TELA Bio's score of -0.02 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TELA Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TELA Bio presently has a consensus price target of $2.20, indicating a potential upside of 143.09%. Inogen has a consensus price target of $13.00, indicating a potential upside of 103.76%. Given TELA Bio's higher probable upside, analysts clearly believe TELA Bio is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Inogen has a net margin of -7.08% compared to TELA Bio's net margin of -49.30%. Inogen's return on equity of -12.90% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
Inogen	-7.08%	-12.90%	-8.27%

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 4.7% of TELA Bio shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Inogen beats TELA Bio on 9 of the 17 factors compared between the two stocks.

How does TELA Bio compare to InfuSystem?

TELA Bio (NASDAQ:TELA) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

InfuSystem has a net margin of 1.12% compared to TELA Bio's net margin of -49.30%. InfuSystem's return on equity of 2.78% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
InfuSystem	1.12%	2.78%	1.41%

TELA Bio presently has a consensus price target of $2.20, indicating a potential upside of 143.09%. InfuSystem has a consensus price target of $15.00, indicating a potential upside of 71.04%. Given TELA Bio's higher probable upside, analysts clearly believe TELA Bio is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.50	-$38.83M	-$0.79	N/A
InfuSystem	$142.40M	1.24	$870K	$0.38	23.08

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 4.7% of TELA Bio shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TELA Bio has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

In the previous week, TELA Bio had 1 more articles in the media than InfuSystem. MarketBeat recorded 9 mentions for TELA Bio and 8 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.87 beat TELA Bio's score of -0.02 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TELA Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InfuSystem	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InfuSystem beats TELA Bio on 12 of the 16 factors compared between the two stocks.

How does TELA Bio compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

TELA Bio has a net margin of -49.30% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
TELA Bio	-49.30%	-1,320.81%	-55.83%

Hyperfine presently has a consensus price target of $1.78, indicating a potential upside of 15.05%. TELA Bio has a consensus price target of $2.20, indicating a potential upside of 143.09%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts clearly believe TELA Bio is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Hyperfine has higher earnings, but lower revenue than TELA Bio. Hyperfine is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	13.32	-$35.57M	-$0.41	N/A
TELA Bio	$80.28M	0.50	-$38.83M	-$0.79	N/A

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 4.7% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hyperfine has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

In the previous week, Hyperfine and Hyperfine both had 9 articles in the media. Hyperfine's average media sentiment score of 0.38 beat TELA Bio's score of -0.02 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
TELA Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Hyperfine and TELA Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get TELA Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELA vs. The Competition

Export

Metric	TELA Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.51M	$3.31B	$6.37B	$12.30B
Dividend Yield	N/A	2.32%	2.80%	5.26%
P/E Ratio	-1.15	18.50	20.66	25.27
Price / Sales	0.50	183.64	531.43	62.35
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	-7.54	6.63	9.87	6.90
Net Income	-$38.83M	$24.40M	$3.57B	$334.66M
7 Day Performance	-11.27%	4.14%	0.23%	0.12%
1 Month Performance	32.54%	-4.80%	-2.54%	-0.18%
1 Year Performance	-17.73%	62.87%	33.54%	30.62%

TELA Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELA TELA Bio	2.9029 of 5 stars	$0.91 -8.6%	$2.20 +143.1%	-17.7%	$40.51M	$80.28M	N/A	120	News Coverage Earnings Report Gap Down
PDEX Pro-Dex	2.4178 of 5 stars	$59.09 +4.6%	$70.00 +18.5%	+37.5%	$188.49M	$66.59M	16.32	140	Positive News Analyst Forecast Analyst Revision
KRMD KORU Medical Systems	3.5417 of 5 stars	$4.01 -0.2%	$7.25 +80.8%	+32.2%	$184.23M	$41.13M	N/A	80
INGN Inogen	3.318 of 5 stars	$6.52 -1.5%	$13.00 +99.4%	+4.8%	$177.89M	$348.67M	N/A	1,030
INFU InfuSystem	4.516 of 5 stars	$8.34 -0.4%	$15.00 +80.0%	+42.6%	$168.32M	$142.40M	138.94	410	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELA) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TELA Bio (TELA) Competitors